Clinical Trials
62 trialsEvaluation of TQ-B3234 Capsules in Patients With Symptomatic, Non-Surgical Type 1 Neurofibromatosis-Associated Plexiform Neurofibromas
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Natural History Study of Patients With Neurofibromatosis Type I
National Institutes of Health Clinical Center (CC)
AZD6244 Hydrogen Sulfate for Children With Nervous System Tumors
National Institutes of Health Clinical Center (CC)
INSPIRE-NF1
Healx Limited
A Study of Selumetinib in Chinese Paediatric and Adult Subjects With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas (PN)
AstraZeneca
A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)
National Institutes of Health Clinical Center (CC)
PEDIA
AstraZeneca
Pediatric Long-Term Follow-up and Rollover Study
Novartis
Individual Patient Compassionate Use of Mirdametinib
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
ReNeu
Merck Healthcare KGaA, Darmstadt, Germany, an affiliate of Merck KGaA, Darmstadt, Germany
Real-World Treatment Study of Koselugo (Selumetinib)
AstraZeneca
Phase I Trial of TURALIO(R) (Pexidartinib, PLX3397) in Children and Young Adults With Refractory Leukemias and Refractory Solid Tumors Including Neurofibromatosis Type 1 (NF1) Associated Plexiform Neurofibromas (PN) and Tenosynovial Giant Cell Tumor ...
National Institutes of Health Clinical Center (CC)
Development and Validation of Patient Reported Outcome (PRO) Measures for Individuals With Neurofibromatosis 1 (NF1) and Plexiform Neurofibromas (pNFs)
National Institutes of Health Clinical Center (CC)
Trametinib for Pediatric Neuro-oncology Patients With Refractory Tumor and Activation of the MAPK/ERK Pathway.
St. Justine's Hospital
KOMET
AstraZeneca
NF114
University of Alabama at Birmingham
NF113
University of Alabama at Birmingham
MEK 1/2 Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
A Study of Avutometinib for People With Solid Tumor Cancers
Memorial Sloan Kettering Cancer Center
NF1-TED
Boston Children's Hospital
PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas
Pasithea Therapeutics Corp.
Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)
National Institutes of Health Clinical Center (CC)
Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1
Ann & Robert H Lurie Children's Hospital of Chicago
Targeting the Mechanisms Underlying Cutaneous Neurofibroma Formation in NF1: A Clinical Translational Approach.
Corewell Health West
Follow-up Study to Evaluate the Safety and Efficacy of FCN-159 in Pediatric Participants With Neurofibromatosis Type 1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
NF108-BINI
University of Alabama at Birmingham
US Selumetinib Registry
Alexion Pharmaceuticals, Inc.
FCN-159 in Adult Patients With Symptomatic, Inoperable Neurofibromatosis Type 1-Related Plexiform Neurofibromas
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
LS-NF1PNs
West China Hospital
Study to Evaluate the Safety, Tolerability, PK Characteristics and Anti-tumor Activity of FCN-159 in Adult and Pediatric Participants With Neurofibromatosis Type 1
Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd.
Medication Adherence in Children, Adolescents and Adults With Neurofibromatosis Type 1(NF1) on Clinical Treatment Trials
National Institutes of Health Clinical Center (CC)
A Retrospective Study on Epidemiological Characteristics of Chinese NF1 Patients in Real World (PROMISE)
Shanghai Ninth People's Hospital Affiliated to Shanghai Jiao Tong University
plexifpc
Region Skane
INSPECT
Great Ormond Street Hospital for Children NHS Foundation Trust
CryoNF1
Centre Leon Berard
PROTECT
AstraZeneca
HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas
Shanghai Kechow Pharma, Inc.
NF105-CABO
University of Alabama at Birmingham
Acceptance and Commitment Training for Adolescents and Young Adults With Neurofibromatosis Type 1, Plexiform Neurofibromas, and Chronic Pain
National Institutes of Health Clinical Center (CC)
Study to Investigate Safety, Pharmacokinetic (PK), Pharmacodynamic (PD) and Clinical Activity of Trametinib in Subjects With Cancer or Plexiform Neurofibromas and Trametinib in Combination With Dabrafenib in Subjects With Cancers Harboring V600 Mutations
Novartis
PET/MRI in CNS and Extra-CNS Tumors of Patients With Neurofibromatosis-1 (NF1)
UNC Lineberger Comprehensive Cancer Center
Whole Body MRI to Identify Atypical Neurofibromas in Patients With NF1
Children's National Research Institute
Study of Imatinib in Children With Neurofibromatosis and Airway Tumors
Indiana University
Clinical Sequencing of Cancer and Tissue Repository: OncoGenomics
National Institutes of Health Clinical Center (CC)
Study of Plexiform Neurofibromas in Neurofibromatosis Type 1
National Institutes of Health Clinical Center (CC)
An Intermediate Access Protocol for Selumetinib for Treatment of Neurofibromatosis Type 1
AstraZeneca
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
National Institutes of Health Clinical Center (CC)
Sorafenib to Treat Children and Young Adults With Neurofibromatosis Type 1 and Inoperable Plexiform Neurofibromas
National Institutes of Health Clinical Center (CC)
Study of Imatinib Mesylate in Neurofibromatosis Type I Patients Aged 2 to 21 With Plexiform Neurofibromas
St. Justine's Hospital
Mitogen Activated Protein Kinase Kinase (MEK1/2) Inhibitor Selumetinib (AZD6244 Hydrogen Sulfate) in People With Neurofibromatosis Type 1 (NF1) Mutated Gastrointestinal Stromal Tumors (GIST)
National Institutes of Health Clinical Center (CC)